Tenax Therapeutics

Tenax Therapeutics is a late-stage pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases with high unmet medical needs. Their primary focus is on pulmonary hypertension, a rare and progressive disorder characterized by abnormally high blood pressure in the pulmonary artery. Tenax is particularly interested in developing disease-modifying therapies for PAH, which currently have no available treatment options.

The company has two primary drug candidates: TNX-201, an oral enteric-coated imatinib mesylate, and TNX-103, an oral levosimendan formulation. TNX-201 has already shown efficacy in a Phase 3 trial for PAH, while TNX-103 has shown promise in Phase 2 trials for pulmonary hypertension in patients with heart failure with preserved ejection fraction (PH-HFpEF). Tenax is working on a unique clinical trial design for TNX-201, which incorporates a novel oral formulation to mitigate gastric intolerance and an enrichment enrollment strategy to maximize treatment effects and minimize risks.

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing therapies that address cardiovascular and pulmonary diseases with high unmet medical need, with a current focus on pulmonary hypertension. The company is committed to bringing innovative and highly efficient clinical trial designs to the market and pursuing a patient-centric, precision medicine approach.

Tenax Therapeutics promotes a culture of innovation and collaboration, with a strong focus on patient-centricity and addressing unmet medical needs. The company prioritizes developing groundbreaking therapies that improve the lives of patients with cardiovascular and pulmonary diseases, particularly pulmonary hypertension. This drive is evident in their commitment to precision medicine, efficient clinical trial design, and working closely with regulatory authorities to ensure a clear pathway to approval. The company's experienced leadership team, consisting of individuals with decades of experience in the pharmaceutical industry, fosters a culture of expertise and knowledge sharing.